NASDAQ · RNTX
Rein Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RNTX: Nov 13, 2026
Rein Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.21.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Dec 2026 | $-0.15 | $-0.15 | $-0.15 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · Quiver Quantitative- Zacks · Sep 3, 11:01 AM EDTHere's Why You Should Add RNTX Stock to Your Portfolio NowRein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026.
- RTTNews · Aug 20, 8:35 AM EDTRein Therapeutics Receives FDA Fast Track Designation For LTI-03 In IPF(RTTNews) – Rein Therapeutics (RNTX), a biopharmaceutical company focused on orphan pulmonary and fibrosis indications, announced that the U.S. FDA has granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis.
- RTTNews · Aug 5, 6:18 AM EDTRein Publishes Clinical Data In Nature Indicating Pulmonary Fibrosis Lung Healing By LTI-03(RTTNews) – Rein Therapeutics Inc. (RNTX), a clinical-stage biopharmaceutical company, reported on Tuesday the publication of clinical results for LTI-03 in treating idiopathic pulmonary fibrosis. The data was published in the Nature Communications scientific journal.
- Zacks · Jun 17, 12:00 PM EDTAll You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to BuyRein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- RTTNews · May 1, 8:13 AM EDTRein Therapeutics Prices $50 Mln Share Offering; Stock Dips In Premarket(RTTNews) – Rein Therapeutics Inc. (RNTX), a clinical-stage biopharmaceutical company, announced the pricing of its 50 million share offering at $1 per share to raise $50 million in gross proceeds.
- RTTNews · Apr 30, 3:23 AM EDTRein Provides Enrollment Update For Phase 2 RENEW Study Of LTI-03 In Idiopathic Pulmonary Fibrosis(RTTNews) – Rein Therapeutics (RNTX), a clinical-stage biopharmaceutical, provided an update on enrollment in its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF).
- Fintel · Feb 4, 4:37 AM ESTRein Therapeutics (RNTX) Price Target Increased by 25.00% to 10.20The average one-year price target for Rein Therapeutics (NasdaqCM:RNTX) has been revised to $10.20 / share. This is an increase of 25.00% from the prior estimate of $8.16 dated January 11, 2026. The price target is an average of many targets provided by analys
- RTTNews · Nov 3, 12:32 PM ESTRein Therapeutics Gets FDA Clearance To Resume Phase 2 Trial Evaluating LTI-03 In Patients With IPF(RTTNews) – Biopharmaceutical company Rein Therapeutics (RNTX), Monday announced that the U.S. Food and Drug Administration has lifted the full clinical hold on the company's phase 2 trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
- Fintel · Sep 30, 8:18 AM EDTRein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20The average one-year price target for Rein Therapeutics (NasdaqCM:RNTX) has been revised to $10.20 / share. This is an increase of 42.86% from the prior estimate of $7.14 dated August 3, 2025. The price target is an average of many targets provided by analysts
- Fintel · Sep 22, 8:03 AM EDTHC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy RecommendationFintel reports that on September 22, 2025, HC Wainwright & Co. initiated coverage of Rein Therapeutics (NasdaqCM:RNTX) with a Buy recommendation.
- Quiver Quantitative · Apr 7, 4:55 PM EDT$RNTX Earnings Results: $RNTX Reports Quarterly Earnings$RNTX ($RNTX) posted quarterly earnings results on Monday, April 7th. The company reported earnings of -$0.26 per share, beating estimates of -$0.49 by $0.23. The company also reported revenue of $0, equaling estimates of $0 by $0.
- Quiver Quantitative · Apr 5, 5:05 PM EDT$RNTX Earnings Preview: Recent $RNTX Insider Trading, Hedge Fund Activity, and More$RNTX ($RNTX) is expected to release its quarterly earnings data on Monday, April 7th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.49 per share.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rein Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.